Efficacy and Safety of Dihydroartemisinin‐Piperaquine (Artekin) in Cambodian Children and Adults with Uncomplicated Falciparum Malaria

Citations Over TimeTop 10% of 2002 papers

Abstract

The safety and efficacy of a novel combination of dihydroartemisinin (DHA) and piperaquine, Artekin (Holleykin Pharmaceuticals), were assessed in 106 patients (76 children and 30 adults) with uncomplicated falciparum malaria from 2 remote areas in Cambodia. Age-based doses were given at 0, 8, 24, and 32 h. Mean total DHA and piperaquine doses were 9.1 and 73.9 mg/kg, respectively, for children and 6.6 and 52.9 mg/kg for adults. All patients became aparasitemic within 72 h. Excluding the results for 1 child who died on day 4, there was a 96.9% 28-day cure rate (98.6% in children and 92.3% in adults). Patients who had recrudescent infection received low doses of Artekin. Side effects were reported by 22 patients (21%) but did not necessitate premature cessation of therapy. Although Artekin is a promising and inexpensive option for antimalarial therapy, further efficacy and pharmacokinetic studies are needed, especially for its use in children.

Related Papers

• → A review of dihydroartemisinin as another gift from traditional Chinese medicine not only for malaria control but also for schistosomiasis control(2014)48 cited
• → The development of an immunoassay for the detection of artemisinin compounds in urine.(1999)13 cited
• → Deuterated antimalarials: Synthesis of trideutero-artemisinin, dihydroartemisinin, and arteether(1996)12 cited
• STUDY OF ON-SITE METHODS OF IN VITRO DETERMINATION OF THE SENSITIVITY OF PLASMODIUM FALCIPARUM TO A NEW ANTIMALARIAL COMPOUND OF DIHYDROARTEMISININ AND PIPERAQUINE(2010)
• → Anticancer Potential of Artemisinin Derivative-Dihydroartemisinin(2023)